Research programme: anti-obesity compounds - SIDRAlternative Names: Anti-obesity compounds research programme - SIDR
Latest Information Update: 05 Nov 2002
At a glance
- Originator Strathclyde Institute for Drug Research
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 05 Nov 2002 Discontinued - Preclinical for Obesity in United Kingdom (unspecified route)
- 01 Sep 2000 Ths programme is available for licensing (http://www.sidr.org)
- 01 Sep 2000 Preclinical development for Obesity in United Kingdom (Unknown route)